«Stealth» nanospheres as new injectable drug carriers: A promising way?;Les nanosphères a «furtives» comme nouvelles formes galéniques injectables: Espoirs et réalités

Medecine/Sciences

Volumn 17, Issue 5, 2001, Pages 619-626

  Dellacherie, Édith ^a   Gref, Ruxandra ^b   Quellec, Patricia ^c  

^a LAB DE CHIM PHYS MACROMOLECULAIRE   (France)

^b UNIV PARIS SUD   (France)

^c SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG CARRIER; NANOPARTICLE; OPSONIN; POLYLACTIC ACID; POLYOXYETHYLENE; POLYSACCHARIDE;

ADSORPTION; DRUG DELIVERY SYSTEM; ENCAPSULATION; HYDROPHILICITY; HYDROPHOBICITY; MACROPHAGE; REVIEW; SURFACE PROPERTY;

EID: 0343337217     PISSN: 07670974     EISSN: None     Source Type: Journal    
DOI: 10.4267/10608/1975     Document Type: Review

References (38)

1. Lewis DH. Controlled release of bioactive agents from lactide/glycolide polymers. In: Chasin M, Langer R, ed. Biodegradable polymers as drug delivery systems. New York: Marcel Dekker, 1990: 1-41.
2. Stossel TP, Mason RJ, Hartwig J, Vaughan M. Quantitative studies of phagocytosis by polymorphonuclear leucocytes. Use of emulsions to measure the initial rate of phagocytosis. J Clin Invest 1972; 51: 615-24.
3. Alonso MJ. Nanoparticulate drug carrier technology. In: Cohen S, Bernstein H, ed. Microparticulate systems for the delivery of proteins and vaccines. Drug and pharmaceutical sciences 1996; 77: 203-42.
4. Gurny R, Peppas NA, Harrington DD, Banker GS. Development of biodegradable and injectable lattices for controlled release of potent drugs. Drug Dev Ind Pharm 1981; 7: 1-25.
5. Blanco MD, Alonso MJ. Development and characterization of protein-loaded poly(lactide-co-glycolide) nanospheres. Eur J Pharmacol Biopharm 1997; 43: 287-94.
6. Müller RH. Colloidal carriers for controlled drug delivery and targeting. Boca Raton: CRC Press, 1991.
7. Petrak K. Design and properties of particulate carriers for intravascular administration. In: Rolland A ed, Pharmaceutical particulate carriers. New York: Marcel Dekker, 1993.
8. Müller BG, Kissel T. Camouflage nanospheres: a new approach to by-passing phagocytic blood clearance by surface modified particulate carriers. Pharm Pharmacol Lett 1993; 3: 67-70.
9. Gref R, Minamitake Y, Peracchia MT, Trubetskoy V, Langer R. Biodegradable long-circulating nanospheres. Science 1994; 263: 1600-3.
10. Peracchia MT, Vauthier C, Passirani C, Couvreur P, Labarre D. Complement consumption by poly(etbylene glycol) in different conformations chemically coupled to poly(isobutyl 2-cyanoacrylate) nanoparticles. Life Sciences 1997; 61: 749-61.
11. Rouzes C, Gref R, Léonard M, Delgado A, Dellacherie E. Surface modification of polylactic acid nanopheres using hydrophobically modified dextrans as stabilizers in an o/w emulsion/evaporation technique. J Biomed Mater Res 2000; 50: 557-65.
12. Ydens I, Rutot D, Degée P, Six JL, Dellacherie E, Dubois P. Controlled synthesis of poly(?-caprolactone)-grafted dextran copolymers as potential environnmentally friendly surfactants. Macromolecules 2000; 33: 6713-21.
13. Peracchia MT, Desmaële D, Couvreur P, d'Angelo J. Synthesis of a novel poly(MePEG cyanoacrylate-co-alkyl cyanoacrylate) amphiphilic copolymer for nanoparticle technology. Macromolecules 1997; 30: 846-51.
14. De Jaeghere F, Allémann E, Leroux JC, et al. Formulation and lyoprotection of poly(lactic acid-co-ethylene oxide) nanoparticles: influence on physical stability and in vitro cell uptake. Pharm Res 1999; 16: 859-66.
15. Quellec P. Nanosphères «furtives» à base de copolymères biodégradables pour la libération contrôléc de principes actifs hydrophobes et de protéines. Thèse de l'Institut National Polytechnique de Lorraine, 1997, Nancy, France.
16. Quellec P, Gref R, Perrin L, et al. Protein encapsulation within polyethylene glycol-coated nanospheres. I. Physicochemical characterization. J Biomed Mater Res 1998; 42: 45-54.
17. Bazile D, Prud'homme C, Bassoullet MT, Marlard M, Spenlehauer G, Veillard M. Stealth MePEG-PLA nanoparticles avoid uptake by the Morphonuclear Phagocyte System. J Pharm Sci 1995; 17: 493-8.
18. 1H-NMR spectroscopy. Biomaterials 1997; 18: 27-30.
19. Tan J, Butterfield C, Voycheck C, Cawell C, Li J. Surface modification of nanoparticles by PEO/PPO block copolymers to minimize the interactions with blood components and prolong blood circulation in rats. Biomaterials 1993; 14: 823-33.
20. Gref R, Lück M, Quellec P, et al. Stealth corona-core nanoparticles modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. Colloid Surface B: Biointerfaces 2000; 18: 301-13.
21. Vittaz, M, Basile D, Spenlehauer G, et al. Effect of PEO surface density on long-circulating PLA-PEO nanoparticles which are very low complement activators. Biomaterials 1996; 17: 1575-81.
22. Zambaux MF, Bonneaux F, Gref R, Dellacherie E, Vigneron C. MPEO-PLA nanoparticles: effect of MPEO content on some of their surface properties. J Biomed Mater Res 1999; 44: 109-15.
23. Peracchia MT, Harnisch S, Pinto-Alphandary H, et al. Vizualization of in vitro protein-rejecting properties of PEGylated stealth polycyanoacrylate nanoparticles. Biomaterials 1999; 20: 1269-75.
24. Gref R, Miralles G, Dellacherie E. Polyoxyethylene-coated nanospheres: effect of coating on zeta potential and phagocytosis. Polym Int 1999; 48: 251-6.
25. De Jaeghere F, Allémann E, Feijen J, Kissel T, Doelker E, Gurny R. Cellular uptake of PEO surface-modified nanoparticles: evaluation of nanoparticles made of PLA: PEO diblock and triblock copolymers. J Drug Target 2000; 8: 143-53.
26. Peracchia MT, Gref R, Minamitake Y, Domb A, Lotan N, Langer R. PEG-coated nanospheres from amphiphilic diblock and multiblock copolymers: investigation of their drug encapsulation and release characteristics. J Control Release 1997; 40: 223-31.
27. Okada H, Toguchi H. Biodegradable microspheres in drug delivery. Crit Rev Therapeut Drug Carrier Syst 1995; 12: 1-99.
28. Youxin L, Volland C, Kissel T. In vitro degradation and bovine serum albumin release of the ABA triblock copolymers consisting of poly(L(+)lactic acid), or poly(L(+)lactic acid-co-glycolic acid) A-blocks attached to central polyoxyethylene B-blocks. J Control Release 1994; 32: 121-8.
29. Bouillot P, Sommer F, Duc TM, Loeffler JP, Dellacherie E. Protein encapsulation in biodegradable amphiphilic microspheres. II. Microsphere characterization and release profiles. Int J Pharm 1999; 181: 159-72.
30. Tobio M, Gref R, Sanchez A, Langer R, Alonso MJ. Stealth PLA-PEG nanoparticles as nasal protein delivery systems. Pharm Res 1998; 15: 274-9.
31. Quellec P, Gref R, Dellacherie E, Sommer F, Tran MD, Alonso MJ. Protein encapsulation within poly(ethylene glycol)-coated nanospheres. II. Controlled release properties. J Biomed Mater Res 1999; 47: 388-95.
32. Song CX, Labhasetwar V, Murphy H, et al. Formulation and characterization of biodegradable nanoparticles for intravascular use. J Control Release 1997; 43: 97-112.
33. Zambaux MF, Bonneaux F, Gref R, Dellacherie É, Vigneron C. Protein C-loaded monomethoxypoly(ethylene oxide)-poly(lactic acid) nanoparticles. Int J Pharm 2001; 212: 1-9.
34. Kirby CJ, Gregoriadis G. Preparation of liposomes containing factor VIII for oral treatment of haemophilia. J Microencapsulation 1984; 1: 33-45.
35. Godsmith JC, Roer MES, Orringer E.P. A new strategy for hemophilia B: incorporation of factor IX into red cell ghosts. Am J Hematol 1979; 7: 119-25.
36. Zambaux MF, Faivre-Fiorina B, Bonneaux F, et al. Involvement of neutrophilic granulocytes in the uptake of biodegradable non-stealth and stealth nanoparticles in guinea pig. Biomaterials 2000; 21: 975-80.
37. Österberg E, Bergström K, Holmberg K, et al. Protein rejecting ability of surface-bound dextran in end-on and side-on configurations: comparison to PEG. J Biomed Mater Res 1995; 29: 741-7.
38. Martin JM. Future prospects for stealth liposomes in cancer therapy. Oncology 1997; 11: 63-8.